Astria Therapeutics Inc. (ATXS)
Astria Therapeutics Statistics
Share Statistics
Astria Therapeutics has 56.43M shares outstanding. The number of shares has increased by 2.77% in one year.
| Shares Outstanding | 56.43M |
| Shares Change (YoY) | 2.77% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 25,923 |
| FTD / Avg. Volume | 7.81% |
Short Selling Information
The latest short interest is 3.15M, so 5.59% of the outstanding shares have been sold short.
| Short Interest | 3.15M |
| Short % of Shares Out | 5.59% |
| Short % of Float | 5.8% |
| Short Ratio (days to cover) | 7.45 |
Valuation Ratios
The PE ratio is -5.36 and the forward PE ratio is -2.69. Astria Therapeutics's PEG ratio is 0.17.
| PE Ratio | -5.36 |
| Forward PE | -2.69 |
| PS Ratio | 0 |
| Forward PS | 0.8 |
| PB Ratio | 1.58 |
| P/FCF Ratio | -6.19 |
| PEG Ratio | 0.17 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Astria Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.49, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.49 |
| Quick Ratio | 17.49 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.07 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,208,461.54 |
| Employee Count | 78 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -44.92% in the last 52 weeks. The beta is 0.68, so Astria Therapeutics's price volatility has been higher than the market average.
| Beta | 0.68 |
| 52-Week Price Change | -44.92% |
| 50-Day Moving Average | 5.59 |
| 200-Day Moving Average | 9.06 |
| Relative Strength Index (RSI) | 52.24 |
| Average Volume (20 Days) | 331,944 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -111.56M |
| Net Income | -94.26M |
| EBITDA | -111.56M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.67 |
Balance Sheet
The company has 59.82M in cash and 5.35M in debt, giving a net cash position of 54.47M.
| Cash & Cash Equivalents | 59.82M |
| Total Debt | 5.35M |
| Net Cash | 54.47M |
| Retained Earnings | -674.79M |
| Total Assets | 342.36M |
| Working Capital | 315.51M |
Cash Flow
In the last 12 months, operating cash flow was -81.21M and capital expenditures -325K, giving a free cash flow of -81.54M.
| Operating Cash Flow | -81.21M |
| Capital Expenditures | -325K |
| Free Cash Flow | -81.54M |
| FCF Per Share | -1.44 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ATXS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ATXS is $28, which is 443.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 443.7% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Aug 20, 2021. It was a backward split with a ratio of 1:6.
| Last Split Date | Aug 20, 2021 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 4.37 |
| Piotroski F-Score | 1 |